KTWOU K2 Capital outlines targeted tech sector acquisition plans in its latest quarterly earnings update Gilead Sciences GILD Valuation Implications of Expanded Kymera Therapeutics Collaboration and Kymeras FDA Fast Track Designation What top holdings OnKure Therapeutics OKUR Smart Money Active 20260427